Results 51 to 60 of about 4,514 (173)

Resistant Plasmodium Falciparum Infection From Samarinda, Kalimantan [PDF]

open access: yes, 1974
Rumah Sakit Caltex di Rumbai, Pekanbaru pernah melaporkan adanya P. falciparum yang resistent terhadap chloroquine. Setelah dilakukan follow up ternyata kasus ini masih sangat sensitive terhadap group 4 aminoquinoline.
Arwati, A. (Arwati), Verdrager, J. (J)
core  

In vivo and in vitro Plasmodium falciparum Resistance to Chloroquine, Amodiaquine and Quinine in the Brazilian Amazon

open access: yesRevista do Instituto de Medicina Tropical de São Paulo, 1997
In order to study the chemoresistance of Plasmodium falciparum to commonly used antimalarial drugs in Brazil the authors have studied ten patients with falciparum malaria, acquired in the Brazilian Amazon region.
Aluisio Augusto Cotrim SEGURADO   +2 more
doaj   +1 more source

Molecular Markers of In Vivo Plasmodium vivax Resistance to Amodiaquine Plus Sulfadoxine-Pyrimethamine: Mutations in pvdhfr and pvmdr1 [PDF]

open access: yes, 2017
Background. Molecular markers for sulfadoxine-pyrimethamine (SP) resistance in Plasmodium vivax have been reported. However, data on the molecular correlates involved in the development of resistance to 4-aminoquinolines and their association with the in
Barbollat, Laetitia   +10 more
core  

In Vitro Screening of an In-House Library of Structurally Distinct Chemotypes Towards the Identification of Novel SARS-CoV-2 Inhibitors

open access: yesPharmaceuticals
Background/Objectives: Four years after the COVID-19 pandemic, a very limited number of drugs has been marketed; thus, the search for new medications still represents a compelling need.
Michele Tonelli   +9 more
doaj   +1 more source

Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. [PDF]

open access: yes, 2016
: We assessed Plasmodium falciparum drug resistance markers in parasites collected in 2012, 2013, and 2015 at 3 sites in Uganda. The prevalence and frequency of parasites with mutations in putative transporters previously associated with resistance to ...
Asua, V   +14 more
core   +2 more sources

Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? [PDF]

open access: yes, 2014
Anti-malarial drugs are now mainly deployed as combination therapy (CT), primarily as a mechanism to prevent or slow the spread of resistance. This strategy is justified by mathematical arguments that generally assume that drug 'resistance' is a binary ...
Hodel, Eva Maria
core   +1 more source

ON- 2-PHENYL-4-AMINOQUINOLINE DERIVATIVES.

open access: yes, 1939
Certain 2-pheny1-4-(dialkylamino-4'-sulphonamidophenyl-, and arnidobenzene- sulphonyl-) aminoquinolines have been described The yield of the condensation pro­duct is invariably poor.
U. P. BASU, P. K. DAS-GUPTA
openaire   +1 more source

Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents. [PDF]

open access: yes, 2017
BACKGROUND: The simian malaria parasite Plasmodium knowlesi is now a well-recognized pathogen of humans in South-East Asia. Clinical infections appear adequately treated with existing drug regimens, but the evidence base for this practice remains weak ...
Blasco, Benjamin   +3 more
core   +1 more source

Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.

open access: yesPLoS Medicine, 2017
BackgroundRadical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Cindy S Chu   +14 more
doaj   +1 more source

Terapèutica antiparasitària [PDF]

open access: yes, 2005
Els paràsits són els més oblidats dels microorganismes patògens. El fet que la seva major prevalença es doni als països de l'àrea tropical, països pobres en la seva major part, potser influeix en aquest fet.
Oliveira, Inés M.
core  

Home - About - Disclaimer - Privacy